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Abstract: BACKGROUND Hemostatic abnormalities have been described in COVID-19, and pulmonary
microthrombosis was consistently found at autopsy with concomitant severe lung damage. METHODS
This is a retrospective observational cross-sectional study including consecutive patients with COVID-19
pneumonia who underwent unenhanced chest CT upon admittance at the emergency room (ER) in one
large academic hospital. QCT was used for the calculation of compromised lung volume (%CL). Clinical
data were retrieved from patients’ files. Laboratory data were obtained upon presentation at the ER.
AIM The aim of this study was to evaluate the correlation between hemostatic abnormalities and lung
involvement in patients affected by COVID-19 pneumonia as described using computer-aided quantitative
evaluation of chest CT (quantitative CT (QCT)). RESULTS A total of 510 consecutive patients (68%
males), aged 67 years in median, diagnosed with COVID-19 pneumonia, who underwent unenhanced
CT scan upon admission to the ER, were included. In all, 115 patients had %CL > 23%; compared
to those with %CL < 23%, they showed higher levels of D-dimer, fibrinogen, and CRP, greater platelet
count, and longer PT ratio. Via multivariate regression analysis, BMI ฀ 30 kg/m2, D-dimer levels > 500
ng/mL, CRP > 5.0 ng/mL and PT ratio > 1.2 were found to be independent predictors of a %CL >
23% (adjusted odds ratios (95% confidence intervals): 2.1 (1.1-4.0), 3.1 (1.6-5.8), 2.4 (1.3-4.5), and 3.4
(1.4-8.5), respectively). CONCLUSIONS Hemostatic abnormalities in patients affected by COVID-19
correlate with the severity of lung injury as measured by %CL. Our results underline the pathogenetic
role of hemostasis in COVID-19 pneumonia beyond the presence of clinically evident thromboembolic
complications.
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Abstract: Background: Hemostatic abnormalities have been described in COVID-19, and pulmonary
microthrombosis was consistently found at autopsy with concomitant severe lung damage. Methods:
This is a retrospective observational cross-sectional study including consecutive patients with COVID-
19 pneumonia who underwent unenhanced chest CT upon admittance at the emergency room
(ER) in one large academic hospital. QCT was used for the calculation of compromised lung
volume (%CL). Clinical data were retrieved from patients’ files. Laboratory data were obtained
upon presentation at the ER. Aim: The aim of this study was to evaluate the correlation between
hemostatic abnormalities and lung involvement in patients affected by COVID-19 pneumonia as
described using computer-aided quantitative evaluation of chest CT (quantitative CT (QCT)). Results:
A total of 510 consecutive patients (68% males), aged 67 years in median, diagnosed with COVID-19
pneumonia, who underwent unenhanced CT scan upon admission to the ER, were included. In all,
115 patients had %CL > 23%; compared to those with %CL < 23%, they showed higher levels of
D-dimer, fibrinogen, and CRP, greater platelet count, and longer PT ratio. Via multivariate regression
analysis, BMI ≥ 30 kg/m2, D-dimer levels > 500 ng/mL, CRP > 5.0 ng/mL and PT ratio > 1.2 were
found to be independent predictors of a %CL > 23% (adjusted odds ratios (95% confidence intervals):
2.1 (1.1–4.0), 3.1 (1.6–5.8), 2.4 (1.3–4.5), and 3.4 (1.4–8.5), respectively). Conclusions: Hemostatic
abnormalities in patients affected by COVID-19 correlate with the severity of lung injury as measured
by %CL. Our results underline the pathogenetic role of hemostasis in COVID-19 pneumonia beyond
the presence of clinically evident thromboembolic complications.
Keywords: COVID-19; lung volume measurements; D-dimer; hemostasis; SARS-CoV-2 pneumonia
1. Introduction
Coronavirus disease 2019 (COVID-19) is a novel, potentially fatal respiratory infec-
tion caused by coronavirus SARS-CoV-2, which was first identified in December 2019 in
Wuhan, Hubei, China [1], and has since spread globally. Europe and the United States of
America have been the epicenters of COVID-19, with a total of 36,607,500 and 50,612,223
confirmed cases and a total of 830,948 and 1,196,316 deaths reported as of 25 February 2021,
respectively [2].
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As the pandemic progressed, the scientific community accelerated the study of pre-
dictors of an unfavorable course, as measured by hospitalization time, need for invasive
ventilation, and the risk of death [3]. An interesting area of knowledge pertains to the
association between hemostatic abnormalities and thrombotic events complicating COVID-
19 pneumonia [4,5]. D-dimer levels were found to be increased in the vast majority of
patients with COVID-19 and represent the main predictor of coagulation-associated com-
plications, as well as death [6,7]. Together with C-reactive protein, platelet count and
erythrocyte sedimentation rate have been reported as the main predictors for thrombotic
events during hospitalization [8]. Indeed, contrast-enhanced CT angiography has unveiled
a high prevalence of acute pulmonary embolism (PE) in severe cases [9,10]. Moreover, the
use of computer-aided quantitative analysis (quantitative computed tomography (QCT)),
measuring the volume of well-aerated and compromised lungs, has also been proven to be
a potential predictor of prognosis [11].
In the present analysis, we used QCT to evaluate the severity of compromised lung
volume (%CL) in a large cohort of patients admitted to an academic hospital and inves-
tigated the potential association between %CL and hemostatic abnormalities occurring
during COVID-19 infection.
2. Materials and Methods
2.1. Subjects
Eligible patients were consecutive patients admitted to the emergency room (ER)
of a large academic hospital in Milan with COVID-19 pneumonia and who underwent
unenhanced chest CT between February and April 2020. Unenhanced chest CT was
performed upon ER admittance in all patients in concomitance with real-time polymerase
chain reaction (RT-PCR) for SARS-CoV-2.
2.2. Study Design
This study was a retrospective, observational, cross-sectional study conducted in
accordance with the amended Declaration of Helsinki. The Institutional Review Board of
IRCCS Humanitas Research Hospital approved the protocol, and written informed consent
was obtained from all patients before every CT exam.
Medical records of patients diagnosed with COVID-19 by means of real-time reverse
transcription–polymerase chain reaction (RT-PCR) were reviewed. Inclusion criteria for this
study were (a) unenhanced chest CT performed upon admission to the ER and (b) COVID-
19 pneumonia. Demographic and clinical data were collected for all patients, including lab-
oratory parameters. Cardiovascular disease (CVD) was defined as known coronary artery
disease, previous stroke/TIA and peripheral artery disease, and/or carotid artery stenosis.
Chronic kidney disease (CKD) was defined as a value of filtration rate < 60 mL/min calcu-
lated using CKD-EPI. PE was searched by CT pulmonary angiography in subjects with an
unexplained clinical worsening of respiratory function or a rapid increase in D-dimer levels
(D-Dimer HS, Instrumental Laboratory Company, Bedford, MA, USA). The International
Society on Thrombosis and Haemostasis (ISTH) score for overt disseminated intravascular
coagulation (DIC) was calculated [12], and DIC was considered present with a score ≥5.
Deaths were also reported.
2.3. Quantitative CT Analysis
All CT scans were performed on a 64-row scanner (Ingenuity, Philips, Amsterdam,
The Netherlands) dedicated to COVID-19 and isolated from the rest of the radiology
department, using standard parameters for chest imaging (100–140 kV, mAs according to
size, slice thickness = 2 mm). DICOM images were exported to 3D-Slicer (www.slicer.org;
last accessed 26 May 2021), which is open-source software for image segmentation and
quantification. The software performed a first-pass, semi-automated segmentation of the
lung parenchyma; missing lung volumes were manually outlined using tools such as
spherical brushes and three-dimensional erasers. A complete segmentation included both
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lungs with interstitial structures, segmentary vessels, and bronchi; the main pulmonary
arteries and bronchi, all mediastinal structures, pleural effusions, and lung masses were
excluded. Contrast-enhanced scans, although available in some cases, were not used
for segmentation purposes as the presence of a contrast medium would have altered the
density of the lung parenchyma.
The whole lung parenchyma was divided into different volume subunits, according to
Hounsfield Units (HU) intervals validated in previous research [13], and categorized into
non-aerated (%NNL, 100, −100 HU), poorly aerated (%PAL, −500, −100 HU), normally
aerated (%NAL, −900, −501 HU), and hyper-inflated (%HIL, −1000, −900 HU). The sum
of %NAL and %HIL defined the normal lung volume, while the sum of %PAL and %NNL
defined the compromised lung volume (%CL, −500, 100 HU) that represents the main
outcome of this study.
2.4. Outcome
The primary objective of this study was to evaluate the correlation between hemostatic
abnormalities and lung damage in patients affected by COVID-19 pneumonia as described
using computer-aided quantitative evaluation of chest CT (quantitative CT (QCT)).
2.5. Statistical Analysis
Continuous variables, expressed as median values and interquartile ranges (IQR), were
compared using the Mann–Whitney U-test. Categorical variables, expressed as frequencies
and percentage values, were compared via the chi-squared test. Correlation coefficients
were calculated using Spearman’s rho tests. %CL > 23% has been considered the primary
outcome because it has been previously related to the worse respiratory outcome [14].
A BMI ≥ 30 kg/m2, a D-dimer value > 500 ng/mL, fibrinogen levels > 550 mg/dL, PT
ratio > 1.20, PLTs count > 200 × 103/mmc, and CRP values > 5 mg/dL were considered
putative risk factors for having a %CL > 23%. Cut-off values for BMI were chosen to identify
obese patients; those for D-dimer and CRP were based on published literature [15,16],
those of fibrinogen and PLT count were based on the median values observed in the
study population, and those for PT were based on the normal laboratory range for this
test. Odds ratios (OR) with 95% confidence intervals (95%CI) were calculated for all
the aforementioned variables via univariate logistic regression analysis (crude OR); all
variables with significant 95%CI were then included in the multivariate model to adjust for
confounders and identify independent predictors of having a %CL > 23% (adjusted OR,
aOR). No missing data imputation was used, and multivariate analysis was performed
including only subjects with complete data. All reported p values are two-sided, and values
<0.05 were considered significant. All analyses were performed using IBM SPSS Statistics
software (version 26.0, IBM Corp., Armonk, New York, NY, USA).
3. Results
In this study, we included 510 consecutive patients (347 males, 68%) aged in median
67 years (interquartile range (IQR), 56–77), who were diagnosed with COVID-19 pneumonia
and underwent unenhanced CT scan upon admission to the ER. The main characteristics
of these subjects are summarized in Table 1.
In all, 384 patients (75%; median age: 62 years, IQR: 53–71) successfully recovered and
were discharged from hospital. A total of 126 (25%; median age 77 years, IQR: 72–84), died
during hospitalization.
Laboratory and clinical parameters upon admission (median, IQR) in survivors and
non-survivors are shown in Table 2. Deceased patients had higher D-dimer and CRP levels,
prolonged PT ratio, higher WBC count, and greater %CL compared to survivors (Table 2).
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Table 1. Main characteristics of the 510 consecutive patients admitted to the emergency room with
COVID-19 pneumonia included in the study.
Characteristics Patients (n = 510)
Median age, years (IQR) 67 (56–77)
Male sex (%) 347 (68)
BMI ≥ 30 kg/m2 (%) 119/478 (25)
Smokers (%) 58/509 (11)
Diabetes (%) 117/508 (23)
Hypertension (%) 251/508 (49)
Cardiovascular disease (%) 121 (24)
COPD (%) 46/508 (9)
CKD (%) 81/508 (16)
Cancer (%) 34/505 (7)
Median %CL (IQR) 12 (7–21)
Median platelet count, ×103/mmc (IQR) 202 (154–267)
Median WBC count, ×103/mmc (IQR) 6.7 (5.2–9.7)
Median D-dimer levels, ng/mL (IQR) 434 (267.2–842.5)
Median fibrinogen levels, mg/dL (IQR) 556 (450–676)
Median prothrombin time ratio (IQR) 1.13 (1.06–1.23)
Median activated partial thromboplastin time ratio (IQR) 0.97 (0.90–1.06)
Median CRP, mg/dL (IQR) 8.8 (3.7–16.2)
BMI = body mass index; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease;
CL = compromised lung; WBC = white blood cells; CRP = C-reactive protein. Normal values for laboratory
parameters: platelets 150–400 × 103/mmc, WBC 4–10 × 103/mmc, D-dimer 200–350 ng/mL, fibrinogen 160–
400 mg/dL, PT ratio 0.9–1.2, aPTT ratio 0.8–1.2, CRP < 1 mg/dL.
Table 2. Clinical and laboratory features of 510 consecutive patients with COVID-19 pneumonia







Median age, years (IQR) 62 (53–71) 77 (72–84) <0.001
Male sex (%) 262 (68) 85 (67) 0.91
BMI ≥ 30 kg/m2 (%) 94/371 (25) 25/107 (23) 0.71
Smokers (%) 37/383 (10) 21 (17) 0.05
Diabetes (%) 73/383 (19) 44/125 (35) <0.001
Hypertension (%) 164/383 (43) 87/125 (70) <0.001
Cardiovascular disease (%) 72 (19) 49 (39) <0.001
COPD (%) 30/383 (8) 16/125 (13) 0.11
CKD (%) 38/383 (10) 43/125 (34) <0.001
Cancer (%) 16/380 (4) 18/125 (14) <0.001
Median %CL (IQR) 11 (6–19) 16 (10-32) <0.001
Median D-dimer levels, ng/mL (IQR) 365 (243–662) 734 (383–2238) <0.001
Median fibrinogen levels, mg/dL (IQR) 552 (454–668) 564 (449–702) 0.61
Median PT ratio (IQR) 1.12 (1.06–1.20) 1.19 (1.08–1.34) <0.001
Median aPTT ratio (IQR) 0.97 (0.91–1.05) 0.97 (0.89–1.09) 0.88
Median platelet count, ×103/mmc (IQR) 204 (163–264) 200 (130–272) 0.09
Median CRP, mg/dL (IQR) 7.7 (3.1–14.4) 13.3 (7.5–21.5) <0.001
Median WBC count, × 103/mmc (IQR) 6.5 (5.2–8.9) 7.9 (5.4–11.9) 0.01
BMI = body mass index; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease;
CL = compromised lung; PT = prothrombin time; aPTT = activated partial thromboplastin time; CRP = C-reactive
protein; WBC = white blood cells. Normal values for laboratory parameters: platelets 150–400 × 103/mmc,
WBC 4–10 × 103/mmc, D-dimer 200–350 ng/mL, fibrinogen 160–400 mg/dL, PT ratio 0.9–1.2, aPTT ratio 0.8–1.2,
CRP < 1 mg/dL.
During the hospital stay, 402 (79%) patients required oxygenation support, this being
via a nasal cannula in 143 (36%), facial mask in 31 (8%), Venturi mask in 84 (21%), helmet
CPAP in 66 (16%), and intubation in 78 (19%). Overall, 86 patients (17%) required ICU
hospitalization, PE was found in 11 patients (2.2%), and DIC occurred in 7 patients (1.4%).
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3.1. Quantitative CT Analysis
All CT scans were of satisfactory quality for analysis. Case examples of QCT with
%CL < or >23% and different texture between %PAL and %NNL are illustrated in Figure 1.
Median %CL was 16% in the deceased group (IQR, 10–32%) and 11% in the recovered
group (IQR, 6–19%). The difference proved statistically significant (p < 0.001; Table 2).
A total of 115 had %CL > 23%. Compared to those with %CL< 23%, they showed
higher levels of D-dimer, fibrinogen, and CRP, greater platelet count, and longer PT ratio
(Table 3). A greater proportion of these patients had BMI ≥ 30 kg/m2 (35% vs 22%,
p = 0.007). No significant difference was found with respect to sex, age, or comorbidities
(Table 3). The need for any type of oxygenation support and the proportion of mechanical










Figure 1. Unenhanced CT scan and QCT analysis in four patients with COVID-19 pneumonia. (A,B) show one QCT with
%CL < 23% and one with %CL > 23%. (C,D) highlight the texture differences between the “poorly aerated” volume (%PAL,
−500, −100 HU) and “non-aerated” volume (%NNL, 100, -100 HU). (A) refers to a 71-year-old man, oxygenated through
nasal cannulae. Upon admission, laboratory tests were as follows: D-dimer 199 ng/mL, fibrinogen 416 mg/dL, PT ratio
1.03, CRP 1.0 mg/dL. %CL was 10%. Non-contrast axial chest CT showed ground-glass opacities, predominantly in the
middle lobe; quantitative analysis highlights poorly aerated lung volumes in yellow (8% PAL) and normally aerated lung
volumes in blue. (B) refers to a 64-year-old man who required mechanical ventilation and intubation. Upon admission,
laboratory tests were as follows: D-dimer 1161 ng/mL, fibrinogen 1021 mg/dL, PT ratio 1.18, CRP 45.3 mg/dL. %CL
was 55%. Non-contrast axial chest CT showed diffuse bilateral ground-glass opacities and posterior lung consolidation;
quantitative analysis highlights non-aerated lung volumes in red (19% NNL), poorly aerated lung volumes in yellow
(36% PAL), and normally aerated lung volumes in blue. (C) refers to a 65-year-old woman who required mechanical
ventilation and intubation. Upon admission, laboratory tests were as follows: PT ratio 1.34, CRP 31.9 mg/dL. %CL was
66%. Non-contrast axial chest CT showed extensive posterior consolidation of the right lower lung lobe and patchy dense
consolidation in the subpleural space of both left lower and upper lung lobes; quantitative analysis highlights poorly
aerated lung volumes in yellow (23% PAL) and non-aerated lung volumes in red (43% NNL). (D) refers to a 66-year-old
man who required mechanical ventilation and intubation. Upon admission, laboratory tests were as follows: D-dimer
1335 ng/mL, fibrinogen 832 mg/dL, PT ratio 1.20, CRP 33.8 mg/dL. %CL was 62%. Non-contrast axial chest CT showed
extensive ground-glass consolidation with “crazy paving” pattern typical of COVID-19; quantitative analysis highlights
normally aerated lung volumes in blue, non-aerated lung volumes in red (12% NNL), and poorly aerated lung volumes in
yellow (50% PAL).
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Table 3. Clinical and laboratory features of 115 patients with COVID-19 pneumonia and >23%
of compromised lung as measured by QTC and comparison with 395 patients with COVID-19









Median age, years (IQR) 68 (58–75) 67 (55–77) 0.43
Male sex (%) 79 (69) 268 (68) 0.91
BMI ≥ 30 kg/m2 (%) 37/105 (35) 82/373 (22) 0.007
Smokers (%) 11/114 (10) 47 (12) 0.62
Diabetes (%) 27/113 (24) 90 (23) 0.80
Hypertension (%) 55/113 (49) 196 (50) 0.92
Cardiovascular disease (%) 26 (23) 95 (24) 0.80
COPD (%) 6/113 (5) 40 (10) 0.14
CKD (%) 22/113 (20) 59 (15) 0.25
Cancer (%) 5/112 (5) 29/395 (7) 0.39
Median %CL (IQR) 33 (27-43) 10 (6-14) <0.001
Median D-dimer levels, ng/mL (IQR) 704 (405–2777) 358 (242–677) <0.001
Median fibrinogen levels, mg/dL (IQR) 639 (515–778) 537 (437–634) <0.001
Median PT ratio (IQR) 1.19 (1.11–1.33) 1.11 (1.06–1.20) <0.001
Median aPTT ratio (IQR) 0.97 (0.87–1.07) 0.97 (0.91–1.05) 0.22
Median platelet count, ×103/mmc (IQR) 246 (177–344) 196 (148–246) <0.001
Median CRP, mg/dL (IQR) 17.4 (10.1–26.2) 7.2 (2.8–13.1) <0.001
Median WBC count, ×103/mmc (IQR) 8.7 (6.4–12.2) 6.1 (5.0–8.7) <0.001
Need for oxygenation support (%) 115 (100) 287 (73) <0.001
Mechanical ventilation (%) 49/115 (43) 29/287 (10) <0.001
Non-survivors (%) 46 (40) 80 (20) <0.001
QCT = quantitative computed tomography; BMI = body m index; COPD = chronic obstructive pulmonary
disease; CKD = chronic kidney disease; CL = compromised lung; PT = prothrombin time; aPTT = activated partial
thromboplastin time; CRP = C-reactive protein; WBC = white blood cells. Normal values for laboratory parameters:
platelets 150–400 × 103/mmc, WBC 4–10 × 103/mmc, D-dimer 200–350 ng/mL, fibrinogen 160–400 mg/dL, PT
ratio 0.9–1.2, aPTT ratio 0.8–1.2, CRP < 1 mg/dL.
Among those 11 patients subsequently diagnosed with PE, only 6 (54%) displayed
%CL > 23%.
A significant correlation was found between %CL and CRP (r2 = 0.58, p < 0.001),
D-dimer (r2 = 0.36, p < 0.001), fibrinogen (r2 = 0.33, p < 0.001), WBC count (r2 = 0.31,
p < 0.001), PT ratio (r2 = 0.28, p < 0.001), platelet count (r2 = 0.22, p < 0.001), and age
(r2 = 0.12, p = 0.005). Figure 2 shows a scatter plot of RCP (A) and D-dimer (B) values in
correlation with %CL value distribution in the study population.






Figure 2. Scatter plot of the distribution of CRP ((A); r2 = 0.58, p < 0.001) and log D-dimer ((B); r2 = 0.36, p < 0.001) levels
according to %CL values in the study population.
3.2. Hemostatic Abnormalities and Compromised Lung
The results of univariate and multivariate logistic regression analysis of potential
determinants of %CL are shown in Table 4. Multivariate analysis was run in 287 patients
with complete clinical and laboratory data. After adjustment, BMI ≥ 30 kg/m2, D-dimer
levels > 500 ng/mL, CRP > 5.0 ng/mL, and PT ratio > 1.2 were found to be independent
predictors of a %CL > 23%.
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Table 4. Univariate and multivariate logistic regression analysis of potential predictors of %CL > 23%
in 287 patients with complete clinical and laboratory data included in the study.
Variable OR (95% CI) adjOR (95% CI)
BMI ≥ 30 kg/m2 1.9 (1.2–3.1) 2.1 (1.1–4.0)
D-dimer levels > 500 ng/mL 2.7 (1.7–4.3) 3.1 (1.6–5.8)
Fibrinogen levels > 400 mg/dL 2.1 (1.0–4.4) 1.5 (0.5–4.3)
PT ratio > 1.20 2.6 (1.7–4.1) 2.4 (1.3–4.5)
Platelet count > 200 × 103/mmc 2.3 (1.5–3.6) 1.9 (0.9–3.5)
CRP > 5 mg/dL 5.6 (2.7–11.5) 3.4 (1.4–8.5)
OR = odds ratio; CI = confidence interval; BMI = body mass index; CL = compromised lung; PT = prothrombin
time; CRP = C-reactive protein.
4. Discussion
In this study, we found that elevated D-dimer levels and prolonged PT values upon
admission in patients affected by COVID-19 pneumonia were independent predictors of
the extent of lung impairment as measured by means of QCT.
Chest CT is the standard imaging technique to identify COVID-19 pneumonia, but it
is limited to visual findings; by contrast, QCT analysis adds knowledge on functional lung
impairment, which is strictly related to the management and prognosis of these patients. In
fact, in a series of 222 patients, compromised lung volume proved to be the most accurate
predictor of the need for respiratory support, with a value >23% meaning being at high
risk for intubation [14]. Similarly, in our series, patients with a %CL > 23% displayed a
greater need for mechanical ventilation as well as increased mortality.
The usefulness of quantifying the volume of the compromised lung from a simple
unenhanced chest CT performed upon admission resides in the fact that this method
can identify minimal changes in voxel units that may not be visible to the unaided eye.
Many studies have reported its use in research on interstitial lung diseases, pulmonary
sarcoidosis, and pulmonary vascular diseases [17–19].
The association between alterations of hemostasis and infections is well known [20].
Elevated levels of D-dimer and fibrin degradation products (FDP) characterize the initial
coagulopathy of COVID-19 pneumonia and have been associated with disease severity and
survival [15,21–24]. Several studies have been conducted to demonstrate a relation between
coagulation parameter derangement and patient outcome, both in terms of ICU admission
and mortality. Indeed, among 183 COVID-19-affected Chinese patients, non-survivors
revealed significantly higher D-dimer and FDP levels, prolonged prothrombin time, and
activated partial thromboplastin time at admission compared to survivors [25]. More
recently, in 67 non-Chinese COVID-19 patients, it was first shown that clotting alterations,
with a trend toward a hypercoagulable state due to increased values of D-dimer and
fibrinogen, were present at the early stage of the disease and are more likely associated
with a more severe form of COVID-19, characterized by severe acute respiratory syndrome
(SARS) [26].
In our study, which includes more than 500 consecutive patients evaluated upon
admission to the ER, we confirm that non-survivors had elevated D-dimer levels and pro-
longed PT ratio, with CRP also being significantly higher in this group of patients. All these
three laboratory markers were found to be independently associated with functional lung
impairment, highlighting that coagulation alterations seen in COVID-19 are strictly related
to the inflammatory response triggered by acute viral infection and that a concerted action
of coagulation and inflammation might be related to the observed lung injury. Indeed,
in a Chinese study including 147 patients, coagulation abnormalities were prominent in
ICU patients, and prolonged PT, elevated FDP, and D-dimer were linearly correlated to
increased levels of IL2R, IL6, IL8, and TNF-α [22].
The hypothesis that a continuous crosstalk between hemostasis and inflammation in-
fluences the severity of lung impairment in COVID-19 patients is suggested by the fact that
pneumocytes and endothelial cells are primary targets of SARS-CoV2 infection [27] and
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that alveolar damage and microvascular thrombosis are the main postmortem histopatho-
logic findings [28]. QCT analysis might reflect the extent of lung injury related to those
physiopathological mechanisms beyond the presence of thromboembolic complications. In
fact, in our cohort, PE was found in a minority, and %CL >23% was found in only half of
them.
Some authors recently hypothesized that pulmonary “thrombosis” rather than “em-
bolism” may be involved in COVID-19 pneumonia [29]; this is also suggested by prelim-
inary data from retrospective reports on the use of dual-energy computed tomography
(DECT) [30,31]. In these studies, DECT imaging also demonstrated pulmonary ischemic
areas in the absence of PE, which could be the consequence of the microvascular lesions
caused by COVID-19 [30,31]. Standardized QCT as presented in our study may have a
similar value to that of DECT, showing patterns of lung function impairment related to the
same microvascular lesions without the need for intravenous contrast injection, and going
beyond the limitations of a subjective radiological interpretation.
Our study has certain limitations: It is a retrospective study; imaging for PE was not
performed in all patients but only in those with clinical suspicion, leading to a possible
underestimation of this feature in our patient population; and there is no histological
evidence of a greater extent/proportion of microvascular lung thrombosis in patients with
greater %CL.
In conclusion, hemostatic abnormalities in patients affected with COVID-19 correlate
with the severity of lung injury as measured by compromised lung volume, a parameter
derived by computer-aided quantitative analysis of non-contrast chest CT that represents a
measure of pulmonary dysfunction as well as a risk factor for a more severe respiratory
outcome and in-hospital mortality. Our results underline the pathogenetic role of hemosta-
sis in COVID-19 pneumonia beyond the presence of clinically evident thromboembolic
complications.
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